Related Experiment Video
Updated: Jun 8, 2026
12:37
Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
Published on: February 9, 2016
I(f) inhibition in cardiovascular diseases
Catherine Thollon1, Jean-Paul Vilaine
1Cardiovascular Department, Institut de Recherches Servier, Suresnes, France.
Advances in Pharmacology (San Diego, Calif.)
|October 12, 2010
Summary
Ivabradine (IVA) is a novel heart rate (HR) lowering drug that selectively inhibits the funny current (I(f)) in sinoatrial node (SAN) cells. This reduces myocardial oxygen demand and has demonstrated anti-anginal and anti-ischemic efficacy in patients with coronary artery disease (CAD).
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Background:
- Heart rate (HR) is primarily regulated by the sinoatrial node (SAN) pacemaker cells, whose spontaneous electrical activity relies on diastolic depolarization (DD).
- The funny current (I(f)), an inward Na+/K+ current mediated by HCN4 channels, is a significant contributor to SAN cell DD and HR regulation.
- Ivabradine (IVA) selectively inhibits I(f) in a use-dependent manner, reducing HR and myocardial oxygen consumption.
Purpose of the Study:
- To review the mechanism of action and therapeutic applications of Ivabradine (IVA) in cardiovascular conditions.
- To highlight IVA's efficacy in managing stable angina and its potential in improving prognosis for coronary artery disease (CAD) and heart failure.
Main Methods:
- Review of existing pharmacological data on Ivabradine (IVA) and its effects on the funny current (I(f)).
- Analysis of clinical trial data assessing IVA's efficacy and safety in patients with stable angina, coronary artery disease (CAD), and heart failure.
- Comparison of IVA's anti-anginal and anti-ischemic effects with traditional treatments like beta-blockers and calcium channel blockers.
Main Results:
- Ivabradine (IVA) effectively reduces heart rate (HR) by inhibiting the funny current (I(f)), leading to decreased myocardial oxygen demand and improved diastolic perfusion.
- IVA demonstrates equipotent anti-anginal and anti-ischemic efficacy compared to beta-blockers and calcium channel blockers in animal models and human studies.
- IVA is well-tolerated, with minor visual side effects, and is the first I(f) inhibitor approved for stable angina treatment.
Conclusions:
- Ivabradine (IVA) represents a significant advancement in the management of stable angina, offering a targeted approach to HR reduction.
- Beyond symptom control, IVA's ability to lower resting HR, an independent predictor of mortality, suggests potential prognostic benefits in CAD and heart failure.
- Further clinical evaluation of IVA is warranted to fully establish its role in improving long-term outcomes for cardiovascular patients.
More Related Videos
08:41Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
09:38Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart
Published on: May 19, 2017
Related Concept Videos
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...